1 | ORKG Ask

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

Gridelli, Cesare
de Castro Carpeno, Javier
Dingemans, Anne-Marie C
Griesinger, Frank
Grossi, Francesco
Langer, Corey
Ohe, Yuichiro
Syrigos, Konstantinos
Thatcher, Nick
Das-Gupta, Ashis
Truman, Matt
Donica, Margarita
Smoljanovic, Vlatka
Bennouna, Jaafar

January 2018

IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic c...

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer The AvaALL Randomized Clinical Trial

Gridelli, Cesare
Carpeno, Javier
Dingemans, Anne-Marie C.
Griesinger, Frank
Grossi, Francesco
Langer, Corey
Ohe, Yuichiro
Syrigos, Konstantinos
Thatcher, Nick
Das-Gupta, Ashis
Truman, Matt
Donica, Margarita
Smoljanovic, Vlatka
Bennouna, Jaafar

December 2018

IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic c...

Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study

Petrioli R.
Francini E.
Fiaschi A. I.
Laera L.
Luzzi L.
Paladini P.
Ghiribelli C.
Voltolini L.
Bianco V.
Roviello G.

January 2015

The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevaci...

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi, F
Scherpereel, A
Gorbunova, V
Gervais, R
Vikstrom, A
Chouaid, C
Chella, A
Kim, Jung-Ha
Ahn, MJ
Reck, M
Pazzola, A
Kim, HT
Aerts, Joachim
Morando, C
Loundou, A
Groen, HJM
Rittmeyer, A

January 2014

The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance...

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer:Updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi, F.
Scherpereel, A.
Gorbunova, V.
Gervais, R.
Vikstrom, A.
Chouaid, C.
Chella, A.
Kim, J. H.
Ahn, M. J.
Reck, M.
Pazzola, A.
Kim, H. T.
Aerts, J. G.
Morando, C.
Loundou, A.
Groen, H. J. M.
Rittmeyer, A.

May 2014

The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance...

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)

Barlesi, Fabrice
Scherpereel, Arnaud
Rittmeyer, Achim
Pazzola, Antonio
Tur, Neus Ferrer
Kim, Joo-Hang
Ahn, Myung-Ju
Aerts, Joachim G. J. V.
Gorbunova, Vera
Vikstrom, Anders
Wong, Elaine K.
Perez-Moreno, Pablo
Mitchell, Lada
Groen, Harry J. M.

August 2013

Purpose Maintenance therapy is associated with improved survival in patients with non-small-cell lun...

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer:AVAPERL (MO22089)

Barlesi, Fabrice
Scherpereel, Arnaud
Rittmeyer, Achim
Pazzola, Antonio
Tur, Neus Ferrer
Kim, Joo-Hang
Ahn, Myung-Ju
Aerts, Joachim G. J. V.
Gorbunova, Vera
Vikstrom, Anders
Wong, Elaine K.
Perez-Moreno, Pablo
Mitchell, Lada
Groen, Harry J. M.

August 2013

PurposeMaintenance therapy is associated with improved survival in patients with non-small-cell lung...

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis

Lopez-Chavez, Ariel
Young, Todd
Fages, Sophie
Leon, Larry
Schiller, Joan H.
Dowlati, Afshin
Brahmer, Julie R.
Johnson, David H.
Sandler, Alan

November 2012

IntroductionThe Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival b...

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi, O.
Rothschild, S.I.
Li, Q.
Matter-Walstra, K.
Zippelius, A.
Betticher, D.C.
Früh, M.
Stahel, R.A.
Cathomas, R.
Rauch, D.
Pless, M.
Peters, S.
Froesch, P.
Zander, T.
Schneider, M.
Biaggi, C.
Mach, N.
Ochsenbein, A.F.

May 2017

Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinu...

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Yasuhiro Tsutani
Yoshihiro Miyata
Takeshi Masuda
Kazunori Fujitaka
Mihoko Doi
Yoshikazu Awaya
Shoichi Kuyama
Soichi Kitaguchi
Kazuhiro Ueda
Noboru Hattori
Morihito Okada

December 2018

Abstract Background We evaluated the safety and efficacy of induction chemotherapy with bevacizumab ...

Effectiveness of maintenance treatments for nonsmall cell lung cancer

Matthew J Eadens
Steven I Robinson
Katharine Ar Price

October 2016

Abstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit...

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial

Gautschi, Oliver
Rothschild, Sacha I.
Li, Qiyu
Matter-Walstra, Klazien
Zippelius, Alfred
Betticher, Daniel C.
Früh, Martin
Stahel, Rolf A.
Cathomas, Richard
Rauch, Daniel
Pless, Miklos
Peters, Solange
Froesch, Patrizia
Zander, Thilo
Schneider, Martina
Biaggi, Christine
Mach, Nicolas
Ochsenbein, Adrian F.
Swiss Group for Clinical Cancer, Research

January 2017

BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy a...

Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous non-small-cell lung cancer: Update from the swiss group for clinical cancer research (SAKK) 19/09 trial

Gautschi, Oliver
Rothschild, Sacha I
Li, Qiyu
Matter-Walstra, Klazien
Zippelius, Alfred
Betticher, Daniel C
Früh, Martin
Stahel, Rolf A
Cathomas, Richard
Rauch, Daniel
Pless, Miklos
Peters, Solange
Froesch, Patrizia
Zander, Thilo
Schneider, Martina
Biaggi, Christine
Mach, Nicolas
Ochsenbein, Adrian F
Swiss Group for Clinical Cancer Research (SAKK)

January 2017

BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy a...

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

Gridelli, Cesare
de Castro Carpeno, Javier
Dingemans, Anne-Marie C
Griesinger, Frank
Grossi, Francesco
Langer, Corey
Ohe, Yuichiro
Syrigos, Konstantinos
Thatcher, Nick
Das-Gupta, Ashis
Truman, Matt
Donica, Margarita
Smoljanovic, Vlatka
Bennouna, Jaafar

January 2018

IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic c...

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer The AvaALL Randomized Clinical Trial

Gridelli, Cesare
Carpeno, Javier
Dingemans, Anne-Marie C.
Griesinger, Frank
Grossi, Francesco
Langer, Corey
Ohe, Yuichiro
Syrigos, Konstantinos
Thatcher, Nick
Das-Gupta, Ashis
Truman, Matt
Donica, Margarita
Smoljanovic, Vlatka
Bennouna, Jaafar

December 2018

IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic c...

Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study

Petrioli R.
Francini E.
Fiaschi A. I.
Laera L.
Luzzi L.
Paladini P.
Ghiribelli C.
Voltolini L.
Bianco V.
Roviello G.

January 2015

The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevaci...

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi, F
Scherpereel, A
Gorbunova, V
Gervais, R
Vikstrom, A
Chouaid, C
Chella, A
Kim, Jung-Ha
Ahn, MJ
Reck, M
Pazzola, A
Kim, HT
Aerts, Joachim
Morando, C
Loundou, A
Groen, HJM
Rittmeyer, A

January 2014

The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance...

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer:Updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Barlesi, F.
Scherpereel, A.
Gorbunova, V.
Gervais, R.
Vikstrom, A.
Chouaid, C.
Chella, A.
Kim, J. H.
Ahn, M. J.
Reck, M.
Pazzola, A.
Kim, H. T.
Aerts, J. G.
Morando, C.
Loundou, A.
Groen, H. J. M.
Rittmeyer, A.

May 2014

The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance...

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)

Barlesi, Fabrice
Scherpereel, Arnaud
Rittmeyer, Achim
Pazzola, Antonio
Tur, Neus Ferrer
Kim, Joo-Hang
Ahn, Myung-Ju
Aerts, Joachim G. J. V.
Gorbunova, Vera
Vikstrom, Anders
Wong, Elaine K.
Perez-Moreno, Pablo
Mitchell, Lada
Groen, Harry J. M.

August 2013

Purpose Maintenance therapy is associated with improved survival in patients with non-small-cell lun...

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer:AVAPERL (MO22089)

Barlesi, Fabrice
Scherpereel, Arnaud
Rittmeyer, Achim
Pazzola, Antonio
Tur, Neus Ferrer
Kim, Joo-Hang
Ahn, Myung-Ju
Aerts, Joachim G. J. V.
Gorbunova, Vera
Vikstrom, Anders
Wong, Elaine K.
Perez-Moreno, Pablo
Mitchell, Lada
Groen, Harry J. M.

August 2013

PurposeMaintenance therapy is associated with improved survival in patients with non-small-cell lung...

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis

Lopez-Chavez, Ariel
Young, Todd
Fages, Sophie
Leon, Larry
Schiller, Joan H.
Dowlati, Afshin
Brahmer, Julie R.
Johnson, David H.
Sandler, Alan

November 2012

IntroductionThe Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival b...

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi, O.
Rothschild, S.I.
Li, Q.
Matter-Walstra, K.
Zippelius, A.
Betticher, D.C.
Früh, M.
Stahel, R.A.
Cathomas, R.
Rauch, D.
Pless, M.
Peters, S.
Froesch, P.
Zander, T.
Schneider, M.
Biaggi, C.
Mach, N.
Ochsenbein, A.F.

May 2017

Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinu...

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Yasuhiro Tsutani
Yoshihiro Miyata
Takeshi Masuda
Kazunori Fujitaka
Mihoko Doi
Yoshikazu Awaya
Shoichi Kuyama
Soichi Kitaguchi
Kazuhiro Ueda
Noboru Hattori
Morihito Okada

December 2018

Abstract Background We evaluated the safety and efficacy of induction chemotherapy with bevacizumab ...

Effectiveness of maintenance treatments for nonsmall cell lung cancer

Matthew J Eadens
Steven I Robinson
Katharine Ar Price

October 2016

Abstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit...

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial

Gautschi, Oliver
Rothschild, Sacha I.
Li, Qiyu
Matter-Walstra, Klazien
Zippelius, Alfred
Betticher, Daniel C.
Früh, Martin
Stahel, Rolf A.
Cathomas, Richard
Rauch, Daniel
Pless, Miklos
Peters, Solange
Froesch, Patrizia
Zander, Thilo
Schneider, Martina
Biaggi, Christine
Mach, Nicolas
Ochsenbein, Adrian F.
Swiss Group for Clinical Cancer, Research

January 2017

BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy a...

Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous non-small-cell lung cancer: Update from the swiss group for clinical cancer research (SAKK) 19/09 trial

Gautschi, Oliver
Rothschild, Sacha I
Li, Qiyu
Matter-Walstra, Klazien
Zippelius, Alfred
Betticher, Daniel C
Früh, Martin
Stahel, Rolf A
Cathomas, Richard
Rauch, Daniel
Pless, Miklos
Peters, Solange
Froesch, Patrizia
Zander, Thilo
Schneider, Martina
Biaggi, Christine
Mach, Nicolas
Ochsenbein, Adrian F
Swiss Group for Clinical Cancer Research (SAKK)

January 2017

BACKGROUND: Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy a...

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

Gridelli, Cesare
de Castro Carpeno, Javier
Dingemans, Anne-Marie C
Griesinger, Frank
Grossi, Francesco
Langer, Corey
Ohe, Yuichiro
Syrigos, Konstantinos
Thatcher, Nick
Das-Gupta, Ashis
Truman, Matt
Donica, Margarita
Smoljanovic, Vlatka
Bennouna, Jaafar

January 2018

IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic c...

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer The AvaALL Randomized Clinical Trial

Gridelli, Cesare
Carpeno, Javier
Dingemans, Anne-Marie C.
Griesinger, Frank
Grossi, Francesco
Langer, Corey
Ohe, Yuichiro
Syrigos, Konstantinos
Thatcher, Nick
Das-Gupta, Ashis
Truman, Matt
Donica, Margarita
Smoljanovic, Vlatka
Bennouna, Jaafar

December 2018

IMPORTANCE Bevacizumab treatment beyond progression has been investigated in breast and metastatic c...

Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study

Petrioli R.
Francini E.
Fiaschi A. I.
Laera L.
Luzzi L.
Paladini P.
Ghiribelli C.
Voltolini L.
Bianco V.
Roviello G.

January 2015

The present study evaluated the efficacy and safety of cisplatin (Cis), gemcitabine (Gem) and bevaci...

1

Abstract

Extracted data

1

Abstract

Extracted data

Related items

Related items